Daniel Garry, MD, PhD

• Minnesota Monthly "Best Doctor" (2014)
• Distinguished Alumni Award, St. John’s University (2010)
• Abbott Endowed Chair in Cardiovascular Sciences, University of Minnesota (2007-present)
• Recipient, Gail Griffiths Hill Endowed Chair in Cardiology, UT Southwestern Medical Center (2004-2007)
• AHA Established Investigator Award (2006)
• Doris Duke Innovation in Clinical Research Award (2001)
• Finalist, ACC Young Investigator’s Award (2001)
• Basil O’Connor Starter Scholar Research Award, March of Dimes Association (2001)
• Winner, AstraZeneca Young Investigator Award (1999)
• Finalist, AHA Council on Circulation Cardiovascular Research Prize (1999)
• Finalist, ACC Young Investigator’s Award (declined, as manuscript was published in Nature) (1999)
• Winner, Astra-Merck Young Investigator Basic Science Research Award (1998)
• Howard Hughes Institutional Scholar Award (1998)
• Winner, American Heart Association, Louis N. Katz Young Investigator Award (1997)

• Fellow, American Heart Association 
• Steering Committee Member, NHLBI Progenitor Cell Biology Consortium 
• PI, Midwestern Progenitor Cell Biology Consortium 
• PI, NHLBI R01 grants, Established Investigator Award of the AHA

Regenerative medicine, Cardiogenesis, and Stem-Cell Biology

Dan’s laboratory has a long-standing interest in regenerative and stem cell biology with a focus on the heart and skeletal muscle. In their studies of the heart and skeletal muscle, the Garry laboratory utilizes an array of technologies including gene disruption strategies, transgenesis, single cell genome analysis, gene editing (TALEN and CRISPR technologies), inducible ES/EB model systems, hiPSC technologies, FACS and other cellular, biochemical and molecular biological techniques. In addition, their use of lower organisms such as zebrafish and newt, which are highly regenerative model systems have successfully uncovered critical regenerative factors. Human iPSCs are another important model for cardiovascular disease investigation for the lab. Using these technologies, the Garry lab was among the first to discover the molecular markers of stem cell populations that regulate critical networks during heart and skeletal muscle development and regeneration. For example, their studies have uncovered novel Ets and Forkhead transcription factors, microRNAs and signaling pathways that direct fate determination of stem cell populations. The manipulation of these pathways using chemical genetics and molecular technologies has provided a platform focused on rebuilding and repairing the injured heart and skeletal muscle.

Care Philosophy

My philosophy is to provide outstanding comprehensive care to patients with cardiovascular disease, including a number of emerging technologies available at the University of Minnesota Medical Center-Fairview. My practice combines state-of-the-art therapies, compassion, and effective communication, creating a working partnership that results (overall) in high quality of life for my patients.

A complete list of publications can be found here: Experts@Minnesota / Daniel J. Garry

• Shi X., Richard J., Zirbes K., Gong W., Lin G., Kyba M., Thomson J.A., Koyano-Nakagawa N., Garry D.J. (2014) Cooperative interaction of Etv2 and Gata2 regulates the development of endothelial and hematopoietic lineages. Developmental Biol., 389:208-218.
• Chann, SS, Shi X, Toyama A, Arpke RW, Dandapat A, Iacovino M, Kang J, Le G, Hagen HR, Garry D.J., Kyba M. (2013) Mesp1 patterns mesoderm into cardiac, hematopoietic, or skeletal myogenic progenitors in a context-dependent manner. Cell Stem Cell, 12:587-601.
• Koyano-Nakagawa N., Kewon J., Iacovino M., Shi X., Rasmussen T.L., Borges L., Zirbes K.M., Li T., Perlingeiro R.C.R., Kyba M., Garry D.J. (2012). Etv2 is expressed in the yolk sac hematopoietic and endothelial progenitors and regulates Lmo2 gene expression. Stem Cells. 30:1611-1623.
• Rasmussen T., Kweon J., Diekman M.A., Belema-Bedada F., Song Q., Bowlin K., Shi X., Ferdous A., Li T., Kyba M., Metzger J.M., Koyano-Nakagawa N., Garry D.J. (2011) ER71 directs mesodermal fate decisions during embryogenesis. Development, 138:4801-4812.
• Caprioli A., Koyano-Nakagawa N., Iacovino M., Shi X., Ferdous A., Harvey R.P., Olson E.N., Kyba M., Garry D.J. (2011). Nkx2-5 represses Gata1 gene expression and modulates the cellular fate of cardiac progenitors during embryogenesis. Circulation. 123:1633-1641.
• Ferdous A., Caprioli A., Iacovino M., Martin C.M., Morris J., Richardson J.A., Latif S., Hammer R.E., Harvey R.P., Olson E.N., Kyba M., Garry, D.J. (2009). Nkx2-5 transactivates the Ets-related protein 71 gene and specifies an endothelial/endocardial fate in the developing embryo. Proc. Natl. Acad. Sci. USA 106:814-819.
• Garry D.J., Olson E.N. (2006). A common progenitor at the heart of development. Cell. 127(6):1101-4.
• Garry D.J., Ordway G.A., Lorenz J.N., Radford N.B., Chin E.R., Grange R.W., Bassel-Duby R., and Williams R.S. (1998) Mice without myoglobin. Nature, 395:905-908.